Professor Uwe Zeymer is an interventional cardiologist at the Klinikum Ludwigshafen (Germany). His interests include acute cardiac care and acute coronary syndromes.
Published: 27 November 2019
Despite advances in cardiovascular therapy, heart failure (HF) continues to be a leading cause of morbidity and mortality with significant cost to the health care system. Evidence for the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan has demonstrated significant reductions in all-cause mortality, cardiovascular mortality, and HF hospitalization compared with enalapril and international guidelines currently recommend its use.
Despite this evidence and the recommendation of clinical guidelines, ARNI therapy is not initiated in the majority of eligible patients. Evidence suggests a lack of understanding of a patient’s risk and also the benefit of life saving therapies by physicians is a primary cause of under-utilization.
Increased education is needed so clinicians fully understand the patient’s risk, as well as latest mechanistic and clinical data to ensure confidence in using newer therapies.
This educational program summarises new data covering ARNI therapy for heart failure with reduced ejection fraction (HFrEF) presented at the European Society of Cardiology (ESC) 2019 congress.
ARIADNE in ReviewWatch now
Commentary on ARIADNEWatch now
PROVE-HF in ReviewWatch now
EVALUATE in ReviewWatch now
Commentary on PROVE-HF and EVALUATEWatch now
TRANSITION-CHF in ReviewWatch now
PIONEER in ReviewWatch now
Commentary on TRANSITION-CHF and PIONEERWatch now